Side effects of anticytokine strategies

Netherlands Journal of Medicine

Volumn 63, Issue 3, 2005, Pages 78-80

  van der Meer, J W M ^a   Popa, C ^a   Netea, M G ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; C REACTIVE PROTEIN; CYTOKINE; CYTOKINE ANTIBODY; DNA ANTIBODY; DOUBLE STRANDED DNA; ETANERCEPT; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; ISONIAZID; MONOCLONAL ANTIBODY; PLACEBO; RECEPTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

APOPTOSIS; ATHEROGENESIS; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOPENIA; DEMYELINATING DISEASE; DISEASE EXACERBATION; DRUG FATALITY; EDITORIAL; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HOST RESISTANCE; HUMAN; INFECTION SENSITIVITY; INFLAMMATORY DISEASE; INTERFERON PRODUCTION; LEUKOCYTE; LEUKOCYTOCLASTIC VASCULITIS; LUPUS ERYTHEMATOSUS; MOLECULAR RECOGNITION; MYCOBACTERIUM; MYCOSIS; NONHODGKIN LYMPHOMA; PATHOGENESIS; PROTEIN EXPRESSION; SALMONELLA; TONSILLITIS; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTITUBERCULAR AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; MYCOBACTERIUM TUBERCULOSIS; RADIOGRAPHY, THORACIC; RISK FACTORS; TONSIL; TUBERCULIN TEST; TUBERCULOSIS, LARYNGEAL; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 15544371476     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (17)

1. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561.
2. Smith JG, Magee DM, Williams DM, Graybill JR. Tumor necrosis factor alpha plays a role in host defense against Histoplasma capsulatum. J Infect Dis 1990;162:1349-53.
3. Echternacher B, Falk W, Mannel DN, Krammer PH. Requirement of endogenous tumor necrosis factor/cachectin for recovery form experimental peritonitis. J Immunol 1990;145:3762-6.
4. Efde MN, Houtman, PM, Spoorenberg JPL, Jansen TLThA. Tonsillar tuberculosis in a rheumatoid arthritis patient receiving anti-TNF alpha (adalimumab) treatment. Neth J Med 2005;63:112-4.
5. Breedveld FC, van Albeda-Kuipers GA, van den Hoogen FHJ. Richtlijn: het toepassen van TNF-blokkade in de behandeling van reumatoide arthritis. Ned Tijschr Reumatol 2004;1:11-2.
6. Arend SM, Breedveld FC, van Dissel JT. TNF-alpha blockade and tuberculosis: better look before you leap. Neth J Med 2003;61:111-9.
7. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
8. Djeu, JY, Blanchard DK, Halkias D, Friedman H. Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-gamma and tumor necrosis factor. J Immunol 1986;137:2980.
9. Netea MG, Radstake T, Joosten LA, van der Meer JWM, Barrera P, Kullberg BJ. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 2003;48:1853-7.
10. Van Dissel JT, Arend SM, Ottenhoff TH. Infections with non-tuberculous mycobacteria and salmonellae in patients with genetic defects in the interleukin-12/interferon-gamma-mediated pathway of macrophage activation. Neth J Med 2001;59:90-4.
11. Arend SM, Janssen R, Gosen JJ, et al. Multifocal osteomyelitis caused by nontuberculous mycobacteria in patients with a genetic defect of the interferon-gamma receptor. Neth J Med 2001;59:140-51.
12. Van der Graaf CA, Netea MG, Drenth JPH, te Morsche RH, van der Meer JWM, Kullberg BJ. Candida-specific interferon-gamma deficiency and toll-like receptor polymorphisms in patients with chronic mucocutaneous candidiasis. Neth J Med 2003;61:365-9.
13. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121(5):1145-57.
14. Hyrich KL, Silman AJ, Watson KD, Symmons DPM. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004;63:1538-43.
15. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-65.
16. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002;86:123-30.
17. Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:303-5.